drugset / Trial / NCT01177410

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

NCT01177410

Phase 2 Completed 148 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.

Timeline

Start
2010-07
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 750 mg
Subject Mesalamine Small molecule 1500 mg